David Dai
Stock Analyst at UBS
(4.10)
# 1,627
Out of 5,014 analysts
109
Total ratings
58%
Success rate
11.5%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Maintained: Buy | $33 | $15.48 | +113.18% | 11 | Sep 29, 2026 | |
| NBTX Nanobiotix | Reiterated: Hold | $30 | $33.10 | -9.37% | 6 | Sep 25, 2026 | |
| BNTX BioNTech SE | Reiterated: Buy | $135 | $99.08 | +36.25% | 3 | Sep 16, 2026 | |
| ENGN enGene Therapeutics | Rated: Hold | $2 | $1.97 | +1.52% | 5 | Sep 16, 2026 | |
| CGON CG Oncology | Rated: Buy | $90 | $69.61 | +29.29% | 5 | Aug 21, 2026 | |
| KURA Kura Oncology | Rated: Buy | $15 | $10.61 | +41.38% | 8 | Aug 21, 2026 | |
| SNDX Syndax Pharmaceuticals | Rated: Buy | $37 → $33 | $17.86 | +84.77% | 5 | Aug 21, 2026 | |
| IOVA Iovance Biotherapeutics | Rated: Hold | $4 → $7 | $10.99 | -36.31% | 4 | Aug 20, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $24 → $27 | $14.95 | +80.60% | 8 | Aug 17, 2026 | |
| KYMR Kymera Therapeutics | Reiterated: Buy | $128 | $112.00 | +14.29% | 3 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $23 → $31 | $23.67 | +30.97% | 6 | Jul 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $31.49 | +42.90% | 2 | Jun 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $69 → $15 | $16.58 | -9.53% | 2 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $31.00 | $16.18 | +91.59% | 13 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 | $0.626 | +139.62% | 2 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 → $8 | $2.50 | +220.00% | 3 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $34 | $197.28 | -82.77% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $546 | $527.67 | +3.47% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $112 | $152.21 | -26.42% | 1 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $38.23 | +30.80% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | ¥2,690 | ¥9,320 | n/a | 6 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ¥34,600 | ¥11,470 | n/a | 1 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | ¥3,900 | ¥3,742 | n/a | 1 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $9.43 | n/a | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $5 | $4.06 | n/a | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $2.67 | n/a | 1 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $54 | $25.60 | n/a | 2 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $28 | $6.35 | n/a | 1 | Mar 30, 2022 |
Summit Therapeutics
Sep 29, 2026
Maintained: Buy
Price Target: $33
Current: $15.48
Upside: +113.18%
Nanobiotix
Sep 25, 2026
Reiterated: Hold
Price Target: $30
Current: $33.10
Upside: -9.37%
BioNTech SE
Sep 16, 2026
Reiterated: Buy
Price Target: $135
Current: $99.08
Upside: +36.25%
enGene Therapeutics
Sep 16, 2026
Rated: Hold
Price Target: $2
Current: $1.97
Upside: +1.52%
CG Oncology
Aug 21, 2026
Rated: Buy
Price Target: $90
Current: $69.61
Upside: +29.29%
Kura Oncology
Aug 21, 2026
Rated: Buy
Price Target: $15
Current: $10.61
Upside: +41.38%
Syndax Pharmaceuticals
Aug 21, 2026
Rated: Buy
Price Target: $37 → $33
Current: $17.86
Upside: +84.77%
Iovance Biotherapeutics
Aug 20, 2026
Rated: Hold
Price Target: $4 → $7
Current: $10.99
Upside: -36.31%
Cullinan Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $24 → $27
Current: $14.95
Upside: +80.60%
Kymera Therapeutics
Aug 5, 2026
Reiterated: Buy
Price Target: $128
Current: $112.00
Upside: +14.29%
Jul 22, 2026
Rated: Buy
Price Target: $23 → $31
Current: $23.67
Upside: +30.97%
Jun 16, 2026
Reiterated: Buy
Price Target: $45
Current: $31.49
Upside: +42.90%
Apr 15, 2026
Downgraded: Hold
Price Target: $69 → $15
Current: $16.58
Upside: -9.53%
Apr 8, 2026
Reiterated: Buy
Price Target: $31.00
Current: $16.18
Upside: +91.59%
Apr 2, 2026
Reiterated: Hold
Price Target: $1.5
Current: $0.626
Upside: +139.62%
Mar 18, 2026
Rated: Buy
Price Target: $7 → $8
Current: $2.50
Upside: +220.00%
Jan 7, 2026
Downgraded: Hold
Price Target: $40 → $34
Current: $197.28
Upside: -82.77%
Nov 7, 2025
Reiterated: Buy
Price Target: $546
Current: $527.67
Upside: +3.47%
Oct 31, 2025
Reiterated: Hold
Price Target: $112
Current: $152.21
Upside: -26.42%
Oct 24, 2025
Reiterated: Buy
Price Target: $50
Current: $38.23
Upside: +30.80%
Apr 2, 2025
Reiterated: Hold
Price Target: ¥2,690
Current: ¥9,320
Upside: n/a
Feb 26, 2025
Reiterated: Buy
Price Target: ¥34,600
Current: ¥11,470
Upside: n/a
Jan 15, 2025
Initiated Coverage: Buy
Price Target: ¥3,900
Current: ¥3,742
Upside: n/a
Sep 29, 2022
Initiated Coverage: Buy
Price Target: $5
Current: $9.43
Upside: n/a
Jul 18, 2022
Downgraded: Hold
Price Target: $40 → $5
Current: $4.06
Upside: n/a
May 16, 2022
Reiterated: Buy
Price Target: $40
Current: $2.67
Upside: n/a
May 9, 2022
Reiterated: Buy
Price Target: $54
Current: $25.60
Upside: n/a
Mar 30, 2022
Initiated Coverage: Buy
Price Target: $28
Current: $6.35
Upside: n/a